Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma

European Radiology

Volumn 20, Issue 8, 2010, Pages 2027-2038

  Lin, Chieh ^a,b   Luciani, Alain ^a,b,d   Itti, Emmanuel ^a,b,c   El Gnaoui, Taoufik ^a   Vignaud, Alexandre ^e   Beaussart, Pauline ^a,b   Lin, Shih Jui ^f   Belhadj, Karim ^a   Brugières, Pierre ^a,b   Evangelista, Eva ^a   Haioun, Corinne ^a,b   Meignan, Michel ^a,b,c   Rahmouni, Alain ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c CNRS   (France)

^d INSERM   (France)

^e Siemens Healthcare   (France)

^f STANFORD UNIVERSITY   (United States)

Author keywords

ADC mapping; Diffuse large B cell lymphoma; Diffusion weighted imaging; FDG PET CT; Respiratory gating; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPH NODE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RESPIRATORY GATED IMAGING; SENSITIVITY AND SPECIFICITY; WHOLE BODY MRI;

ADULT; AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 77957937858     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-1758-y     Document Type: Article

References (45)

1. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253
2. Kwee TC, Kwee RM, Nievelstein RA (2008) Imaging in staging of malignant lymphoma: a systematic review. Blood 111:504-516
3. Moog F, Bangerter M, Diederichs CG et al (1997) Lymphoma: role of wholebody 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203:795-800
4. Moog F, Bangerter M, Diederichs CG et al (1998) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206:475-481
5. Schaefer NG, Hany TF, Taverna C et al (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232:823-829
6. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586
7. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578
8. Schoder H, Noy A, Gonen M et al (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651
9. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59
10. Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632
11. Itti E, Lin C, Dupuis J et al (2009) Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at four cycles of chemotherapy. J Nucl Med 50:527-533
12. Sumi M, Ichikawa Y, Nakamura T (2007) Diagnostic ability of apparent diffusion coefficients for lymphomas and carcinomas in the pharynx. Eur Radiol 17:2631-2637
13. Nakayama T, Yoshimitsu K, Irie H et al (2004) Usefulness of the calculated apparent diffusion coefficient value in the differential diagnosis of retroperitoneal masses. J Magn Reson Imaging 20:735-742
14. King AD, Ahuja AT, Yeung DK et al (2007) Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion-weighted MR imaging. Radiology 245:806-813
15. Toh CH, Castillo M, Wong AM et al (2008) Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 29:471-475
16. Takahara T, Imai Y, Yamashita T et al (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275-282
17. Thoeny HC, De Keyzer F (2007) Extracranial applications of diffusionweighted magnetic resonance imaging. Eur Radiol 17:1385-1393
18. Koh DM, Collins DJ (2007) Diffusionweighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 188:1622-1635
19. Kwee TC, Takahara T, Ochiai R et al (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18:1937-1952
20. Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (New York, NY 11:102-125
21. Lichy MP, Aschoff P, Plathow C et al (2007) Tumor detection by diffusionweighted MRI and ADC-mapping-initial clinical experiences in comparison to PET-CT. Invest Radiol 42:605-613
22. Li S, Xue HD, Li J et al (2008) Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma. Chin Med Sci J 23:138-144
23. Stecco A, Romano G, Negru M et al (2009) Whole-body diffusion-weighted magnetic resonance imaging in the staging of oncological patients: comparison with positron emission tomography computed tomography (PET-CT) in a pilot study. Radiol Med 114:1-17
24. Kwee TC, Quarles van Ufford HM, Beek FJ et al (2009) Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 44:683-690
25. Rahmouni A, Luciani A, Itti E (2005) Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria). Cancer Imaging 5 (Spec No A): S102-S106
26. Picardi M, Soricelli A, Pane F et al (2009) Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. Radiology 251:574-582
27. Koh DM, Takahara T, Imai Y et al (2007) Practical aspects of assessing tumors using clinical diffusionweighted imaging in the body. Magn Reson Med Sci 6:211-224
28. Nguyen TD, de Rochefort L, Spincemaille P et al (2008) Effective motion-sensitizing magnetization preparation for black blood magnetic resonance imaging of the heart. J Magn Reson Imaging 28:1092-1100
29. Uto T, Takehara Y, Nakamura Y et al (2009) Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 252:247-254
30. Bernstein MA, King KF, Zhou ZJ (2004) Handbook of MRI pulse sequences. Elsevier Academic Press, Amsterdam
31. Luciani A, Vignaud A, Cavet M et al (2008) Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 249:891-899
32. Kato H, Kanematsu M, Tanaka O et al (2009) Head and neck squamous cell carcinoma: usefulness of diffusionweighted MR imaging in the prediction of a neoadjuvant therapeutic effect. Eur Radiol 19:103-109
33. Rini JN, Leonidas JC, Tomas MB et al (2003) 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44:1072-1074
34. de Jong PA, van Ufford HM, Baarslag HJ et al (2009) CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol 192:745-753
35. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
36. Mori T, Nomori H, Ikeda K et al (2008) Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 3:358-364 (Pubitemid 351489475)
37. Ho KC, Lin G, Wang JJ et al (2009) Correlation of apparent diffusion coefficients measured by 3T diffusionweighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging 36:200-208
38. Komori T, Narabayashi I, Matsumura K et al (2007) 2-[Fluorine-18]-fluoro- 2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 21:209-215
39. Kwee TC, Takahara T, Koh DM et al (2008) Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 28:1141-1148
40. Wang J, Takashima S, Takayama F et al (2001) Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 220:621-630
41. Pileri SA, Dirnhofer S, Went P et al (2002) Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 41:482-509
42. Hunt KE, Reichard KK (2008) Diffuse large B-cell lymphoma. Arch Pathol Lab Med 132:118-124
43. Vandecaveye V, De Keyzer F, Vander Poorten V et al (2009) Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 251:134-146
44. Reese TG, Heid O, Weisskoff RM et al (2003) Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med 49:177-182
45. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994